News
OBI Pharma Awarded Level-A Recognition for TIPS Management
OBI Pharma, Taiwan (4174) announced that it has been awarded a “Level-A” rating by auditors from the government-sponsored TIPS (Taiwan Intellectual Property Management System) project, …
OBI Pharma Granted OBI 833 Patents for Taiwan and Australia
OBI Pharma, Taiwan (4174) announced that it has been granted Taiwan and Australian patents protecting OBI-833, its new cancer vaccine comprised of the Globo H …
OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO
OBI Pharma is pleased to provide video highlights from the successful company-sponsored symposium that took place at the 2016 European Society for Medical Oncology (ESMO) …
Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine
In response to Next Magazine’s continuous and malicious publication of misleading stories against our client, OBI Pharma Inc. (hereinafter referred to as “OBI”), we, Formosan …
OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting
Experts Examine the Future of Active Immunotherapy in Oncology and the potential role of Adagloxad Simolenin (OBI-822) TAIPEI, TAIWAN, September 6, 2016 – OBI Pharma, …